Figure 2.
Figure 2. Growth of cell lines in MTS assays following treatment with daunorubicin or imatinib. (A) Cell growth (survival and proliferation) after 2 days of culture in the presence of the indicated concentrations of daunorubicin was measured by colorimetric MTS assay in the presence or absence of 10 μg/mL verapamil. The absorbance is shown as a percentage of the absorbance for same cells cultured in the absence of daunorubicin. (B) Cell growth (survival and proliferation) after 3 days of culture in the presence of the indicated concentrations of imatinib was measured by the MTS assay. HEL erythroleukemia cells, which do not express BCR/ABL, were used as a control for parental and transduced K562 cells. The absorbance is shown as a percentage of the absorbance for same cells cultured in the absence of imatinib. The error bars show the SEM for triplicate samples at each dose of drug.

Growth of cell lines in MTS assays following treatment with daunorubicin or imatinib. (A) Cell growth (survival and proliferation) after 2 days of culture in the presence of the indicated concentrations of daunorubicin was measured by colorimetric MTS assay in the presence or absence of 10 μg/mL verapamil. The absorbance is shown as a percentage of the absorbance for same cells cultured in the absence of daunorubicin. (B) Cell growth (survival and proliferation) after 3 days of culture in the presence of the indicated concentrations of imatinib was measured by the MTS assay. HEL erythroleukemia cells, which do not express BCR/ABL, were used as a control for parental and transduced K562 cells. The absorbance is shown as a percentage of the absorbance for same cells cultured in the absence of imatinib. The error bars show the SEM for triplicate samples at each dose of drug.

Close Modal

or Create an Account

Close Modal
Close Modal